Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Parallel, Placebo-Controlled Phase III Study to Evaluate the Safety and Antiviral Activity of Clevudine (L-FMAU) 30 mg QD in Patients With HBeAg Negative Chronic Hepatitis B

NCT00313274 is registered in ClinicalTrials.gov with Bukwang Pharmaceutical as lead sponsor.

NCT NCT00313274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00313274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Parallel, Placebo-Controlled Phase III Study to Evaluate the Safety and Antiviral Activity of Clevudine (L-FMAU) 30 mg QD in Patients With HBeAg Negative Chronic Hepatitis B
Lead sponsor
Bukwang Pharmaceutical
Phase
Phase 3
Overall status
Terminated
Start date
July 31, 2003
Completion date
December 31, 2004
Enrollment
80
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b